Amphastar Pharma Stock Price, News & Analysis

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2025 financial results with net revenues of $170.5M, slightly down 1% from $171.8M in Q1 2024. GAAP net income was $25.3M ($0.51 per share), compared to $43.2M ($0.81 per share) in Q1 2024. BAQSIMI® sales surged 177% to $38.4M, while Primatene MIST® grew 20% to $29.1M. However, Glucagon and Epinephrine sales declined 27% and 29% respectively due to increased competition. The company's pipeline includes 4 ANDAs and 1 biosimilar insulin candidate filed with FDA, targeting products with >$3B market size. The FDA's acceptance of AMP-004 insulin biosimilar application marks a significant milestone for their biosimilar portfolio expansion.

Amphastar Pharmaceuticals has scheduled its Q1 2025 earnings release and conference call for May 7th, 2025. The company will disclose financial results after market close, followed by a conference call at 2:00 p.m. Pacific Time.

Amphastar, a bio-pharmaceutical company, specializes in developing and manufacturing complex injectable, inhalation, and intranasal products. Their product portfolio includes technically challenging generic and proprietary medications, primarily used in hospitals and urgent care settings. The company also produces insulin API products and distributes through group purchasing organizations and drug wholesalers.

Investors can join the conference call via toll-free number 877-407-0989 or international number 201-389-0921. A webcast will be available on the company's website, with a replay accessible within 24 hours after the live call.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will be represented by CFO Bill Peters and SVP of Corp. Communication Dan Dischner in an analyst-moderated fireside chat scheduled for Wednesday, April 9th, 2025, at 1:30 pm ET.

The presentation will be accessible through Amphastar's investor relations website at http://ir.amphastar.com, with the webcast remaining available for 30 days following the event.

Amphastar Pharmaceuticals (NASDAQ:AMPH) subsidiary International Medication Systems (IMS) has received the FDA's Drug Shortage Assistance Award for addressing the shortage of epinephrine injection 0.1 mg/mL syringes. The recognition highlights IMS's efforts in submitting and obtaining approval of a new drug application for epinephrine injection.

The company's pipeline includes 4 ANDAs targeting products with >$2 billion market size, 4 biosimilar products targeting >$7 billion market size, and 2 generic products targeting >$1.3 billion market size, based on IQVIA data for 2024. Amphastar is developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference. The company will be represented by Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, who are scheduled to present on Wednesday, March 12th, 2025, at 10:30 am ET.

Interested parties can access the presentation through Amphastar's investor relations website at http://ir.amphastar.com. The webcast recording will remain accessible for 30 days following the presentation.

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported strong financial results for Q4 and full year 2024. Q4 revenues reached $186.5 million with GAAP net income of $38.0 million ($0.74 per share) and adjusted non-GAAP net income of $47.2 million ($0.92 per share).

For the full year 2024, the company achieved net revenues of $732.0 million, GAAP net income of $159.5 million ($3.06 per share), and adjusted non-GAAP net income of $200.8 million ($3.86 per share). Notable achievements include exceeding $100 million in annual sales for Primatene MIST and BAQSIMI showing 12% factory sales growth compared to Q4 2023.

The company's pipeline includes four ANDAs targeting products with >$2 billion market size, four biosimilar products targeting >$7 billion market size, and two generic products targeting >$1.3 billion market size. Operating cash flow for 2024 was $213.4 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its Q4 2024 earnings release for February 27, 2025, after market close. The company will host a conference call at 2:00 p.m. Pacific Time to discuss financial results.

Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also sells insulin API products, with most finished products distributed through group purchasing organizations and drug wholesalers for hospital or urgent care clinical settings.

The company highlights its transition towards high-value and high-growth areas market, including the integration of BAQSIMI®, and its focus on branded products, proprietary products, and biosimilars.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO and President Jack Zhang, along with CFO Bill Peters, will deliver a presentation on Wednesday, January 15th, 2025, at 11:15 am PST.

The presentation will be accessible through a webcast on Amphastar's website at http://ir.amphastar.com. Interested parties can access the webcast recording for 30 days following the presentation.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Bill Peters, CFO, and Dan Dischner, SVP of Corporate Communication, will engage in an analyst-moderated fireside chat on December 4th, 2024 at 11:30 am EST. The presentation will be accessible through Amphastar's website at ir.amphastar.com, with the webcast remaining available for 30 days after the event.